Profile of Polish patients with progressive forms of multiple sclerosis Review article
Article Sidebar
Published:
Sep 30, 2019
Keywords:
multiple sclerosis, progressive form, epidemiology, treatment perspectives
Main Article Content
Abstract
In its initial stadium, multiple sclerosis (MS) has most frequently the form of relapsing-remitting (RRMS), which after a period of time transforms into the form of secondary progressive (SPMS). Regular increase of disability from the very beginning of the disease occurs at ca. 10% of patients, most frequently without overlapping relapses (PPMS, primary progressive multiple sclerosis). Epidemiological data concerning the progressive form are very scanty. A commonly- accepted definition or the criteria of identifying SPMS do not exist; nor is the profile of Polish patients suffering from progressive multiple sclerosis known. In this paper, on the basis of recent publications, the frequency of occurrence of various disease forms was discussed, and clinical, demographical, and social differences between RRMS, PPMS, and SPMS were analysed.
Due to registration of new medication, which raises a lot of hope for patients suffering from PPMS (ocrelizumab) and SPMS (siponimod), the data may be crucial during pharmacological and economic analysis and estimation of counts of potential groups of patients that could undergo the treatment.
Article Details
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
2. Kingwell E, Marriott JJ, Jette N et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 2013; 13: 128: 1-13.
3. Brola W, Sobolewski P, Flaga S et al. Prevalence and incidence of multiple sclerosis in central Poland, 2010-2014. BMC Neurol 2016; 16(1): 134.
4. Brola W, Sobolewski P, Flaga S et al. Increasing prevalence and incidence of multiple sclerosis in Poland. Neurol Neurochir Pol 2017; 51(1): 82-85.
5. Ontaneda D. Progressive Multiple Sclerosis. Continuum (Minneap Minn) 2019; 25(3): 736-752.
6. Manouchehrinia A, Zhu F, Piani-Meier D et al. Predicting risk of secondary progression in multiple sclerosis: A nomogram. Mult Scler 2019; 25(8): 1102-1112.
7. Lublin FD, Reingold SC, Cohen JA et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83(3): 278-286.
8. Thompson AJ, Polman CH, Miller DH et al. Primary progressive multiple sclerosis. Brain 1997; 120: 1085-1096.
9. Cottrell DA, Kremenchutzky M, Rice GPA et al. The natural history of multiple sclerosis: a geographically based study: 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122: 625-639.
10. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007; 6(10): 903-912.
11. Antel J, Antel S, Caramanos Z et al. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol 2012; 123(5): 627-638.
12. Thompson AJ, Banwell BL, Barkhof F et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162-173.
13. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129: 606-616.
14. Lorscheider J, Buzzard K, Jokubaitis V et al. Defining secondary progressive multiple sclerosis. Brain 2016; 139(Pt 9): 2395-2405.
15. Kappos L, Bar-Or A, Cree BAC et al. EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391(10127): 1263-1273.
16. Jacobs LD, Wende KE, Brownscheidle CM et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler 1999; 5: 369-376.
17. Salter A, Thomas NP, Tyry T et al. A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry. Mult Scler 2018; 24(7): 951-962.
18. Weinshenker BG, Bass G, Rice GP et al. The natural history of multiple sclerosis: a geographically based study: 1. Clinical course and disability. Brain 1989; 112: 133-146.
19. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005; 65: 1919-1923.
20. Flachenecker P, Stuke K, Elias W et al. Multiple sclerosis registry in Germany: results of the extension phase 2005/2006. Dtsch Arztebl Int 2008; 105(7): 113-119.
21. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343(20): 1430-1438.
22. Kułakowska A, Bartosik-Psujek H, Hożejowski R et al. Selected aspects of the epidemiology of multiple sclerosis in Poland – a multicentre pilot study. Neurol Neurochir Pol 2010; 44(5): 443-452.
23. Mitosek-Szewczyk K, Kułakowska A, Bartosik-Psujek H et al. Quality of life in Polish patients with multiple sclerosis. Adv Med Sci 2014; 59(1): 34-38.
24. Pierzchala K, Adamczyk-Sowa M, Dobrakowski P et al. Demographic characteristics of MS patients in Poland’s upper Silesia region. Int J Neurosci 2015; 125(5): 344-351.
25. Brola W, Sobolewski P, Fudala M et al. Self-reported quality of life in multiple sclerosis patients: preliminary results based on the Polish MS Registry. Patient Prefer Adherence 2016; 10: 1647-1656.
26. Kapica-Topczewska K, Brola W, Fudala M et al. Prevalence of multiple sclerosis in Poland. Mult Scler Relat Disord 2018; 21: 51-55.
27. Brola W, Sobolewski P, Żak M et al. Profile of Polish patients with primary progressive multiple sclerosis. Mult Scler Relat Disord 2019; 33: 33-38.
28. Baldassari LE, Fox RJ. Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. Drugs 2018; 78(15): 1549-1566.
29. Montalban X, Hauser SL, Kappos L et al. ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376(3): 209-220.
2. Kingwell E, Marriott JJ, Jette N et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 2013; 13: 128: 1-13.
3. Brola W, Sobolewski P, Flaga S et al. Prevalence and incidence of multiple sclerosis in central Poland, 2010-2014. BMC Neurol 2016; 16(1): 134.
4. Brola W, Sobolewski P, Flaga S et al. Increasing prevalence and incidence of multiple sclerosis in Poland. Neurol Neurochir Pol 2017; 51(1): 82-85.
5. Ontaneda D. Progressive Multiple Sclerosis. Continuum (Minneap Minn) 2019; 25(3): 736-752.
6. Manouchehrinia A, Zhu F, Piani-Meier D et al. Predicting risk of secondary progression in multiple sclerosis: A nomogram. Mult Scler 2019; 25(8): 1102-1112.
7. Lublin FD, Reingold SC, Cohen JA et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83(3): 278-286.
8. Thompson AJ, Polman CH, Miller DH et al. Primary progressive multiple sclerosis. Brain 1997; 120: 1085-1096.
9. Cottrell DA, Kremenchutzky M, Rice GPA et al. The natural history of multiple sclerosis: a geographically based study: 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122: 625-639.
10. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007; 6(10): 903-912.
11. Antel J, Antel S, Caramanos Z et al. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol 2012; 123(5): 627-638.
12. Thompson AJ, Banwell BL, Barkhof F et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162-173.
13. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129: 606-616.
14. Lorscheider J, Buzzard K, Jokubaitis V et al. Defining secondary progressive multiple sclerosis. Brain 2016; 139(Pt 9): 2395-2405.
15. Kappos L, Bar-Or A, Cree BAC et al. EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391(10127): 1263-1273.
16. Jacobs LD, Wende KE, Brownscheidle CM et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler 1999; 5: 369-376.
17. Salter A, Thomas NP, Tyry T et al. A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry. Mult Scler 2018; 24(7): 951-962.
18. Weinshenker BG, Bass G, Rice GP et al. The natural history of multiple sclerosis: a geographically based study: 1. Clinical course and disability. Brain 1989; 112: 133-146.
19. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005; 65: 1919-1923.
20. Flachenecker P, Stuke K, Elias W et al. Multiple sclerosis registry in Germany: results of the extension phase 2005/2006. Dtsch Arztebl Int 2008; 105(7): 113-119.
21. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343(20): 1430-1438.
22. Kułakowska A, Bartosik-Psujek H, Hożejowski R et al. Selected aspects of the epidemiology of multiple sclerosis in Poland – a multicentre pilot study. Neurol Neurochir Pol 2010; 44(5): 443-452.
23. Mitosek-Szewczyk K, Kułakowska A, Bartosik-Psujek H et al. Quality of life in Polish patients with multiple sclerosis. Adv Med Sci 2014; 59(1): 34-38.
24. Pierzchala K, Adamczyk-Sowa M, Dobrakowski P et al. Demographic characteristics of MS patients in Poland’s upper Silesia region. Int J Neurosci 2015; 125(5): 344-351.
25. Brola W, Sobolewski P, Fudala M et al. Self-reported quality of life in multiple sclerosis patients: preliminary results based on the Polish MS Registry. Patient Prefer Adherence 2016; 10: 1647-1656.
26. Kapica-Topczewska K, Brola W, Fudala M et al. Prevalence of multiple sclerosis in Poland. Mult Scler Relat Disord 2018; 21: 51-55.
27. Brola W, Sobolewski P, Żak M et al. Profile of Polish patients with primary progressive multiple sclerosis. Mult Scler Relat Disord 2019; 33: 33-38.
28. Baldassari LE, Fox RJ. Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. Drugs 2018; 78(15): 1549-1566.
29. Montalban X, Hauser SL, Kappos L et al. ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376(3): 209-220.